In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent

• Authors: BACCARANI M.; IACOBUCCI I.; CHIARETTI S.; FOA R.; BALASUBRAMANIAN P.; PAIETTA E.; FORONI L.; JEROMIN S.; IZZO B.; SPINELLI O.; VARMA N.; MENIF S.; TERRAGNA C.; SETH T.; BIDET A.; CORIU D.; LUNGHI F.; MAYER Jiří; SCAPPINI B.; LANGABEER S.; MAIER J.; BURT E.; CANDONI A.; ALBANO F.; LUPPI M.; ZUPAN I.; LION T.; ZADRO R.; DI RAIMONDO F.; POOPAK B.; REGE-CAMBRIN G.; ANNUNZIATA M.; AYALA A.; SALINAS-VIEDMA V.; INES PADO A.; MILNER B.; GALIMBERTI S.; JANSSEN J.; POLLI V.; COMBA L.; BORSELLINO B.; ANNIBALI O.; CRUGNOLA M.; PASSAMONTI F.
• Year of publication: 2020
• Type: Article in Periodical
• Magazine / Source: Leukemia
• MU Faculty or unit: Faculty of Medicine
• Web: https://www.nature.com/articles/s41375-019-0591-9
• Doi: http://dx.doi.org/10.1038/s41375-019-0591-9
• Keywords: acute lymphoblastic leukemia
• Description: Philadelphia-chromosome positive (Ph+), BCR-ABL1+ acute lymphoblastic leukemia (ALL) is a distinct entity that is characterized by specific genomic alterations, low sensitivity to chemotherapy, unstable responsiveness to tyrosine kinase inhibitors (TKIs), and a poor prognosis.